Critical requirement for Stat5 in a mouse model of polycythemia vera.
about
Recent advances in understanding myelofibrosis and essential thrombocythemiaSignal transduction in the chronic leukemias: implications for targeted therapiesRuxolitinib in the treatment of polycythemia vera: patient selection and special considerationsPAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesisStem and progenitor cell subsets are affected by JAK2 signaling and can be monitored by flow cytometry.Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?The role of glucocorticoid receptor (GR) polymorphisms in human erythropoiesis.JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic responseEssential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice.Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in miceThe PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasmsStat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiencyMolecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.Myeloproliferative neoplasm animal modelsTherapy with JAK2 inhibitors for myeloproliferative neoplasms.Hematopoietic stem cells, progenitor cells and leukemic stem cells in adult myeloproliferative neoplasms.The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective.Oxidative metabolism in cancer: A STAT affair?Stat5-deficient hematopoiesis is permissive for Myc-induced B-cell leukemogenesis.Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation.Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses.A Genetic Screen Reveals an Unexpected Role for Yorkie Signaling in JAK/STAT-Dependent Hematopoietic Malignancies in Drosophila melanogaster.Acetylation and sumoylation control STAT5 activation antagonistically.Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm.Jak2V617F driven myeloproliferative neoplasm occurs independently of interleukin-3 receptor beta common signaling.Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation.Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia.Application of mutant JAK2V617F for in vitro generation of red blood cells.Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms.Pharmacologic inhibition of STAT5 in acute myeloid leukemia.Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype.Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2.Deletion of Ptpn1 induces myeloproliferative neoplasm.
P2860
Q26748543-D9F29662-6A23-48BC-B436-416891A25892Q27026031-F5D74815-B436-4C33-A74A-0531D9FD82D8Q28078404-F9C12CCE-0460-4DD7-8E61-876FF6D30509Q28302461-5A98D6D7-AA11-4C1D-A2F5-C74B5CBB64EBQ31156217-DAC8C1FE-084D-4F48-A4AC-48DC1849D692Q33697252-92A58DCA-B0D1-4E99-AE1F-394ED46AFD15Q33709629-1C958E30-7B93-4AA7-AB82-A738ACCD456CQ35144757-15E60892-7D99-4B0D-A8B4-CF1A0CA535F5Q35163764-A34B7BED-8C93-4EA3-B78D-0D117EC6A221Q35885308-352DAD3C-A33C-4129-AFD2-A6F4C595BAA9Q36137458-78311E41-150F-49E0-836C-C2A16B1F4062Q36206435-C576B0B4-DA9A-4D44-A008-A61DA2256134Q36545566-93AF01CA-AB12-4F58-8CC7-93B4EB335C7BQ37058122-FA5AC145-0B38-4596-B1DD-CE54F94CD9AFQ37168138-B8DE761F-5B00-45D0-A93B-ADC044A41C78Q37304113-38B72574-BD31-4B11-88C9-B297697801B2Q37555785-0E20F40D-329A-4503-A720-D6B073072CE6Q38046320-D666A4DD-AAE2-4F85-8FF1-EE20D75FAD02Q38046321-88C9B0F3-A80F-4AAA-A905-C44DC3D6CDB5Q38046648-2910F89E-978A-47EC-AF32-85FA4EA451A2Q38140890-DFD081EB-72B6-46F4-8F1C-EDEF7E641940Q38177820-2393B7CC-E1AB-4696-A3DB-CBA903DA3C82Q38285935-CAD84469-9A17-4EC5-9D76-6EAFCC3C34C1Q38586919-5ED203EE-A103-415A-96CF-60104A77C78EQ38699339-003AD581-F67A-42FB-BFCA-EDE88A1F2A62Q39010230-8A9564B6-3695-4AC8-BF70-2C15AD38EC78Q39448829-92E54B11-F8DE-4717-B709-7CAD13A09524Q41380766-084FDE14-86A0-433B-9191-A6FE38021E2EQ41390061-1E594252-73C4-4FA3-BA77-632A7A1328C0Q41418744-35741F28-ADCA-4480-A18F-20767BA90AC1Q41555800-3C719A10-BEC7-4349-9019-7366CFF35B38Q42923861-234BC344-DA9B-4455-878F-F251AEDD419BQ48569638-5E879443-7BE0-444E-AD02-A987E54A0534Q49887981-593507E3-A5FD-496E-B0BC-423BBD4B3C5BQ50276743-25358EED-4162-4186-AA3A-7A259CE9FCB1Q51354558-B2BF8043-B787-4D65-949A-ECE7C49F0CDDQ52689082-1344348A-A524-4EB2-BD29-A1B830F3EDEBQ53129470-0D6980A1-C3B3-47AE-B738-46F08D580B79Q55311942-E4AE92EA-37D9-4B01-8683-D37470C86FA0Q55316434-902C2132-6A55-411A-9BDF-B8816580DDDE
P2860
Critical requirement for Stat5 in a mouse model of polycythemia vera.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Critical requirement for Stat5 in a mouse model of polycythemia vera.
@ast
Critical requirement for Stat5 in a mouse model of polycythemia vera.
@en
type
label
Critical requirement for Stat5 in a mouse model of polycythemia vera.
@ast
Critical requirement for Stat5 in a mouse model of polycythemia vera.
@en
prefLabel
Critical requirement for Stat5 in a mouse model of polycythemia vera.
@ast
Critical requirement for Stat5 in a mouse model of polycythemia vera.
@en
P2093
P2860
P1433
P1476
Critical requirement for Stat5 in a mouse model of polycythemia vera.
@en
P2093
Dongqing Yan
Golam Mohi
Robert E Hutchison
P2860
P304
P356
10.1182/BLOOD-2011-03-345215
P407
P577
2011-12-05T00:00:00Z